Suppr超能文献

血清白蛋白水平对接受自体造血干细胞移植的淋巴瘤患者预后的影响。

Prognostic Role of Serum Albumin Level in Patients with Lymphoma Undergoing Autologous Stem Cell Transplantation.

机构信息

Center for Hematology, Southwest Hospital, Third Military Medical University, Chongqing, China (mainland).

Key Laboratory of Cancer Immunotherapy of Chongqing, Chongqing, China (mainland).

出版信息

Ann Transplant. 2021 Oct 12;26:e933365. doi: 10.12659/AOT.933365.

Abstract

BACKGROUND High-dose chemotherapy followed by autologous stem cell transplantation (HDT/ASCT) plays a crucial role in the therapy of patients with lymphoma. This retrospective study aimed to analyze prognostic factors in patients undergoing HDT/ASCT for lymphoma. MATERIAL AND METHODS We included patients with lymphoma who underwent HDT/ASCT at our center. Time-to-event outcomes, including progression-free survival (PFS) and overall survival (OS), were analyzed with the Kaplan-Meier method and log-rank test. Receiver operating characteristic (ROC) curve analysis and Cox proportional hazard regression analysis were performed to explore the prognostic value of different factors. RESULTS A total of 113 patients with lymphoma were included. Patients with low serum albumin levels (<37 g/L) before transplantation had significantly lower PFS and OS (P<0.01). Albumin levels before transplantation significantly predicted early progression (progressed within 1 year) after transplantation (AUC=0.706, P=0.003). Multivariate Cox analysis indicated that low albumin level (hazard ratio [HR] 3.19, 95% confidence interval [CI] 1.54-6.63; P=0.002) and age >60 years (HR 2.92, 95% CI 1.27-6.71; P=0.012) were independent risk factors for PFS. Total protein <60 g/L was an independent risk factor for OS (HR 3.57, 95% CI 1.45-8.78; P=0.006). CONCLUSIONS Low albumin level before transplantation was an independent risk factor in patients with lymphoma undergoing HDT/ASCT. Intense care and effective maintenance therapy after transplantation are required for patients with low albumin levels.

摘要

背景

大剂量化疗联合自体造血干细胞移植(HDT/ASCT)在淋巴瘤患者的治疗中起着至关重要的作用。本回顾性研究旨在分析接受 HDT/ASCT 的淋巴瘤患者的预后因素。

材料和方法

我们纳入了在我院接受 HDT/ASCT 的淋巴瘤患者。采用 Kaplan-Meier 法和对数秩检验分析无进展生存(PFS)和总生存(OS)等时间事件结局。采用接收者操作特征(ROC)曲线分析和 Cox 比例风险回归分析探讨不同因素的预后价值。

结果

共纳入 113 例淋巴瘤患者。移植前血清白蛋白水平<37 g/L 的患者 PFS 和 OS 明显降低(P<0.01)。移植前白蛋白水平显著预测移植后早期进展(1 年内进展)(AUC=0.706,P=0.003)。多因素 Cox 分析表明,低白蛋白水平(危险比[HR]3.19,95%置信区间[CI]1.54-6.63;P=0.002)和年龄>60 岁(HR 2.92,95%CI 1.27-6.71;P=0.012)是 PFS 的独立危险因素。总蛋白<60 g/L 是 OS 的独立危险因素(HR 3.57,95%CI 1.45-8.78;P=0.006)。

结论

移植前低白蛋白水平是接受 HDT/ASCT 的淋巴瘤患者的独立危险因素。对于低白蛋白水平的患者,移植后需要进行强化护理和有效的维持治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7b4/8518521/6dd952e781b7/anntransplant-26-e933365-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验